Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
8168 participants
Study Classification
OBSERVATIONAL
Study Start Date
2020-03-23
Study Completion Date
2020-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators propose to select all COVID 19 patients attended in any health center (with in hospital beds), who have been discharged or have died at the time of the evaluation.
The main objective of the present study is to carefully characterize the clinical profile of patients infected with COVID-19 in order to develop a simple prognostic clinical score allowing, in selected cases, rapid logistic decision making (discharge with follow-up, referral to provisional/field hospitals or admission to more complex hospital centers).
As secondary objectives, the analysis of the risk-adjusted influence of treatments and previous comorbidities of patients infected with the disease will be performed.
The main objective of the present study is to carefully characterize the clinical profile of patients infected with COVID-19 in order to develop a simple prognostic clinical score allowing, in selected cases, rapid logistic decision making (discharge with follow-up, referral to provisional/field hospitals or admission to more complex hospital centers).
As secondary objectives, the analysis of the risk-adjusted influence of treatments and previous comorbidities of patients infected with the disease will be performed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain
NCT04355871
Covid19
COMPLETED
International COVID-19 Clinical Evaluation Registry -2 (HOPE-2)
NCT04778020
Covid19
COMPLETED
Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry
NCT04347278
SARS-CoV-2
UNKNOWN
Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER
NCT04341142
CoV2 Positive Caregivers
ACTIVE_NOT_RECRUITING
NA
Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est
NCT04366206
COVID
SARS-CoV 2
UNKNOWN
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
INTRODUCTION. The disease caused by the new respiratory virus (coronavirus) designated as SARS-CoV-2 has recently been classified as a pandemic by the WHO.
With an increasing number of confirmed cases in most countries worldwide, it is responsible for a significant morbidity and mortality and has motivated the implementation of measures at national and international levels with a great impact on the way of life of people throughout the whole planet.
In addition, this condition currently threatens many countries with the collapse of health systems, producing serious logistical problems due to extensive affectation of the population, which can worsen the prognosis of those primarily affected by COVID 19 and other patients with different pathologies and who may have difficulties to get healthcare.
Limited clinical information is available and generally limited to the Asian population, since the first cases were identified in Wuhan (Hubei, China).
PURPOSE. The main objective of the present study is to carefully characterize the clinical profile of patients infected with COVID-19 in order to develop a simple prognostic clinical score allowing, in selected cases, rapid logistic decision making (discharge with follow-up, referral to provisional/field hospitals or admission to more complex hospital centers).
As secondary objectives, the analysis of the risk-adjusted influence of treatments (ie. ACEIs, ARBs) and previous comorbidities of patients infected with the disease will be performed.
DESIGN AND STATISTICAL ANALYSIS Cross-sectional and ambispective registry, a real life "all comers" type, with voluntary participation, without funding or conflicts of interest. It is a study initiated by researcher that will have advanced statistical support from the IMAS foundation (Institute for the Improvement of Health Care, Madrid, Spain), that will serve as statistical core.
International level.
PARTICIPANTS PROTOCOL. The study has been approved by Hospital Clinico San Carlos Ethic´s Committee (20/241-E) and the institutional board of each participating center. It has received an AEMPS classification (EPA-0D).
The researchers aimto select all the patients attended in any health center (with in hospital beds), who have been discharged or have died at the time of the evaluation.
All will be considered eligible with a positive COVID 19 test (any type) or if their attending physicians consider them highly likely to have presented the infection.
Given the anonymous characteristics of the registry and the health alarm situation generated by the virus, in principle, it is not considered necessary to provide written informed consent.
\- Inclusion criteria Patients discharged (deceased or alive) from any hospital center with a confirmed diagnosis or a COVID-19 high suspicion.
There are no exclusion criteria, except for the patient's explicit refusal to participate.
DATA BASE. An anonymized database is presented in electronic format, to be filled in at each participating center (www.HopeProjectMD.com).
In theory, all information could be obtained from electronic records (medical history).
If deemed necessary, the investigator may call patients in order to establish their vital status (strongly warranted), as well as the results of the RNA test (or antibody) , if they were pending during their stay.
SAMPLE SIZE. It would not be possible to estimate for the sample size based on literature reports. Thus, HOPE will aim to get the maximum numbers of patients possible.
OUTCOMES. Primary: All-cause mortality. The major contributors of increased mortality will be assessed.
Secondary: In stay events, defined by the attending physician.
* In hospital stay.
* Heart failure.
* Renal failure.
* Respiratory Insufficiency.
* Upper respiratory tract involvement.
* Pneumonia.
* Sepsis.
* Systemic inflammatory response Syndrome.
* Clinically relevant bleeding.
* Hemoptysis.
* Embolic event
* Other complications.
* Causes of death. Depending the results of the main interim analysis, the main DB could be slightly modified and several sub analyses could be proposed after sensitivity analyses.
With an increasing number of confirmed cases in most countries worldwide, it is responsible for a significant morbidity and mortality and has motivated the implementation of measures at national and international levels with a great impact on the way of life of people throughout the whole planet.
In addition, this condition currently threatens many countries with the collapse of health systems, producing serious logistical problems due to extensive affectation of the population, which can worsen the prognosis of those primarily affected by COVID 19 and other patients with different pathologies and who may have difficulties to get healthcare.
Limited clinical information is available and generally limited to the Asian population, since the first cases were identified in Wuhan (Hubei, China).
PURPOSE. The main objective of the present study is to carefully characterize the clinical profile of patients infected with COVID-19 in order to develop a simple prognostic clinical score allowing, in selected cases, rapid logistic decision making (discharge with follow-up, referral to provisional/field hospitals or admission to more complex hospital centers).
As secondary objectives, the analysis of the risk-adjusted influence of treatments (ie. ACEIs, ARBs) and previous comorbidities of patients infected with the disease will be performed.
DESIGN AND STATISTICAL ANALYSIS Cross-sectional and ambispective registry, a real life "all comers" type, with voluntary participation, without funding or conflicts of interest. It is a study initiated by researcher that will have advanced statistical support from the IMAS foundation (Institute for the Improvement of Health Care, Madrid, Spain), that will serve as statistical core.
International level.
PARTICIPANTS PROTOCOL. The study has been approved by Hospital Clinico San Carlos Ethic´s Committee (20/241-E) and the institutional board of each participating center. It has received an AEMPS classification (EPA-0D).
The researchers aimto select all the patients attended in any health center (with in hospital beds), who have been discharged or have died at the time of the evaluation.
All will be considered eligible with a positive COVID 19 test (any type) or if their attending physicians consider them highly likely to have presented the infection.
Given the anonymous characteristics of the registry and the health alarm situation generated by the virus, in principle, it is not considered necessary to provide written informed consent.
\- Inclusion criteria Patients discharged (deceased or alive) from any hospital center with a confirmed diagnosis or a COVID-19 high suspicion.
There are no exclusion criteria, except for the patient's explicit refusal to participate.
DATA BASE. An anonymized database is presented in electronic format, to be filled in at each participating center (www.HopeProjectMD.com).
In theory, all information could be obtained from electronic records (medical history).
If deemed necessary, the investigator may call patients in order to establish their vital status (strongly warranted), as well as the results of the RNA test (or antibody) , if they were pending during their stay.
SAMPLE SIZE. It would not be possible to estimate for the sample size based on literature reports. Thus, HOPE will aim to get the maximum numbers of patients possible.
OUTCOMES. Primary: All-cause mortality. The major contributors of increased mortality will be assessed.
Secondary: In stay events, defined by the attending physician.
* In hospital stay.
* Heart failure.
* Renal failure.
* Respiratory Insufficiency.
* Upper respiratory tract involvement.
* Pneumonia.
* Sepsis.
* Systemic inflammatory response Syndrome.
* Clinically relevant bleeding.
* Hemoptysis.
* Embolic event
* Other complications.
* Causes of death. Depending the results of the main interim analysis, the main DB could be slightly modified and several sub analyses could be proposed after sensitivity analyses.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
COVID 19
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
CROSS_SECTIONAL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Observational (registry)
Observational study.
Intervention Type
COMBINATION_PRODUCT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients discharged (deceased or alive) from any hospital center with a confirmed diagnosis or a COVID-19 high suspicion.
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IVAN J NUÑEZ GIL
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
IVAN J NUÑEZ GIL
Principal Investigator. Attending Physician. MD, PhD, FESC
Responsibility Role
SPONSOR_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Lclinico San Carlos
Madrid, , Spain
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Spain
References
Explore related publications, articles, or registry entries linked to this study.
Nunez-Gil IJ, Estrada V, Fernandez-Perez C, Feltes G, Vedia O, Vergara-Uzcategui CE, Moreno-Menguia VH, Cerrato E, D'Ascenzo F, Raposeiras-Roubin S, Martin-Sanchez FJ, Alfonso-Rodriguez E, Huang J, Ramakrishna H, Gil-Higes E, Fernandez-Ortiz A, Macaya C. Health Outcome Predictive Evaluation for COVID 19 international registry (HOPE COVID-19), rationale and design. Contemp Clin Trials Commun. 2020 Dec;20:100654. doi: 10.1016/j.conctc.2020.100654. Epub 2020 Sep 23.
Reference Type
BACKGROUND
Uribarri A, Nunez-Gil IJ, Aparisi A, Arroyo-Espliguero R, Maroun Eid C, Romero R, Becerra-Munoz VM, Feltes G, Molina M, Garcia-Aguado M, Cerrato E, Capel-Astrua T, Alfonso-Rodriguez E, Castro-Mejia AF, Raposeiras-Roubin S, Espejo C, Perez-Sole N, Bardaji A, Marin F, Fabregat-Andres O, D'ascenzo F, Santoro F, Akin I, Estrada V, Fernandez-Ortiz A, Macaya C; HOPE COVID-19 investigators. Atrial fibrillation in patients with COVID-19. Usefulness of the CHA2DS2-VASc score: an analysis of the international HOPE COVID-19 registry. Rev Esp Cardiol (Engl Ed). 2021 Jul;74(7):608-615. doi: 10.1016/j.rec.2020.12.009. Epub 2021 Jan 13.
Reference Type
BACKGROUND
Pepe M, Maroun-Eid C, Romero R, Arroyo-Espliguero R, Fernandez-Rozas I, Aparisi A, Becerra-Munoz VM, Garcia Aguado M, Brindicci G, Huang J, Alfonso-Rodriguez E, Castro-Mejia AF, Favretto S, Cerrato E, Albiol P, Raposeiras-Roubin S, Vedia O, Feltes Guzman G, Carrero-Fernandez A, Perez Cimarra C, Buzon L, Jativa Mendez JL, Abumayyaleh M, Corbi-Pascual M, Macaya C, Estrada V, Nestola PL, Biondi-Zoccai G, Nunez-Gil IJ. Clinical presentation, therapeutic approach, and outcome of young patients admitted for COVID-19, with respect to the elderly counterpart. Clin Exp Med. 2021 May;21(2):249-268. doi: 10.1007/s10238-021-00684-1. Epub 2021 Feb 8.
Reference Type
BACKGROUND
Rivera-Caravaca JM, Nunez-Gil IJ, Vivas D, Viana-Llamas MC, Uribarri A, Becerra-Munoz VM, Trabattoni D, Fernandez Rozas I, Feltes G, Lopez-Pais J, El-Battrawy I, Macaya C, Fernandez-Ortiz A, Estrada V, Marin F; HOPE COVID-19 Investigators. Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID-19. Eur J Clin Invest. 2021 Jan;51(1):e13436. doi: 10.1111/eci.13436. Epub 2020 Nov 7.
Reference Type
RESULT
Nunez-Gil IJ, Fernandez-Perez C, Estrada V, Becerra-Munoz VM, El-Battrawy I, Uribarri A, Fernandez-Rozas I, Feltes G, Viana-Llamas MC, Trabattoni D, Lopez-Pais J, Pepe M, Romero R, Castro-Mejia AF, Cerrato E, Astrua TC, D'Ascenzo F, Fabregat-Andres O, Moreu J, Guerra F, Signes-Costa J, Marin F, Buosenso D, Bardaji A, Raposeiras-Roubin S, Elola J, Molino A, Gomez-Doblas JJ, Abumayyaleh M, Aparisi A, Molina M, Guerri A, Arroyo-Espliguero R, Assanelli E, Mapelli M, Garcia-Acuna JM, Brindicci G, Manzone E, Ortega-Armas ME, Bianco M, Trung CP, Nunez MJ, Castellanos-Lluch C, Garcia-Vazquez E, Cabello-Clotet N, Jamhour-Chelh K, Tellez MJ, Fernandez-Ortiz A, Macaya C; HOPE COVID-19 Investigators. Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry. Intern Emerg Med. 2021 Jun;16(4):957-966. doi: 10.1007/s11739-020-02543-5. Epub 2020 Nov 9.
Reference Type
RESULT
Nunez-Gil IJ, Estrada V, Fernandez-Perez C, Fernandez-Rozas I, Martin-Sanchez FJ, Macaya C. The COVID-19 curve, health system overload, and mortality. Emergencias. 2020 Ago;32(4):293-295. No abstract available. English, Spanish.
Reference Type
RESULT
Uribarri A, Nunez-Gil IJ, Aparisi A, Becerra-Munoz VM, Feltes G, Trabattoni D, Fernandez-Rozas I, Viana-Llamas MC, Pepe M, Cerrato E, Capel-Astrua T, Romero R, Castro-Mejia AF, El-Battrawy I, Lopez-Pais J, D'Ascenzo F, Fabregat-Andres O, Bardaji A, Raposeiras-Roubin S, Marin F, Fernandez-Ortiz A, Macaya C, Estrada V; HOPE COVID-19 Investigators. Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry. J Nephrol. 2020 Aug;33(4):737-745. doi: 10.1007/s40620-020-00790-5. Epub 2020 Jun 29.
Reference Type
RESULT
Nunez-Gil IJ, Fernandez-Ortiz A, Maroud Eid C, Huang J, Romero R, Becerra-Munoz VM, Uribarri A, Feltes G, Trabatoni D, Fernandez-Rozas I, Viana-Llamas MC, Pepe M, Cerrato E, Bertaina M, Capel Astrua T, Alfonso E, Castro-Mejia AF, Raposeiras-Roubin S, D'Ascenzo F, Espejo Paeres C, Signes-Costa J, Bardaji A, Fernandez-Perez C, Marin F, Fabregat-Andres O, Akin I, Estrada V, Macaya C. Underlying heart diseases and acute COVID-19 outcomes. Cardiol J. 2021;28(2):202-214. doi: 10.5603/CJ.a2020.0183. Epub 2020 Dec 21.
Reference Type
RESULT
Becerra-Munoz VM, Nunez-Gil IJ, Eid CM, Garcia Aguado M, Romero R, Huang J, Mulet A, Ugo F, Rametta F, Liebetrau C, Aparisi A, Fernandez-Rozas I, Viana-Llamas MC, Feltes G, Pepe M, Moreno-Rondon LA, Cerrato E, Raposeiras-Roubin S, Alfonso E, Carrero-Fernandez A, Buzon-Martin L, Abumayyaleh M, Gonzalez A, Fernandez Ortiz A, Macaya C, Estrada V, Fernandez-Perez C, Gomez-Doblas JJ. Clinical profile and predictors of in-hospital mortality among older patients hospitalised for COVID-19. Age Ageing. 2021 Feb 26;50(2):326-334. doi: 10.1093/ageing/afaa258.
Reference Type
RESULT
Ruiz-Sanchez JG, Nunez-Gil IJ, Cuesta M, Rubio MA, Maroun-Eid C, Arroyo-Espliguero R, Romero R, Becerra-Munoz VM, Uribarri A, Feltes G, Trabattoni D, Molina M, Garcia Aguado M, Pepe M, Cerrato E, Alfonso E, Castro Mejia AF, Roubin SR, Buzon L, Bondia E, Marin F, Lopez Pais J, Abumayyaleh M, D'Ascenzo F, Rondano E, Huang J, Fernandez-Perez C, Macaya C, de Miguel Novoa P, Calle-Pascual AL, Estrada Perez V, Runkle I; HOPE COVID-19 investigators. Prognostic Impact of Hyponatremia and Hypernatremia in COVID-19 Pneumonia. A HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry Analysis. Front Endocrinol (Lausanne). 2020 Nov 30;11:599255. doi: 10.3389/fendo.2020.599255. eCollection 2020.
Reference Type
RESULT
El-Battrawy I, Nunez-Gil IJ, Abumayyaleh M, Estrada V, Manuel Becerra-Munoz V, Uribarri A, Fernandez-Rozas I, Feltes G, Arroyo-Espliguero R, Trabattoni D, Lopez-Pais J, Pepe M, Romero R, Castro-Mejia AF, Cerrato E, Capel Astrua T, D'Ascenzo F, Fabregat-Andres O, Signes-Costa J, Marin F, Buonsenso D, Bardaji A, Jesus Tellez M, Fernandez-Ortiz A, Macaya C, Akin I. COVID-19 and the impact of arterial hypertension-An analysis of the international HOPE COVID-19 Registry (Italy-Spain-Germany). Eur J Clin Invest. 2021 Nov;51(11):e13582. doi: 10.1111/eci.13582. Epub 2021 Aug 19.
Reference Type
RESULT
Signes-Costa J, Nunez-Gil IJ, Soriano JB, Arroyo-Espliguero R, Eid CM, Romero R, Uribarri A, Fernandez-Rozas I, Aguado MG, Becerra-Munoz VM, Huang J, Pepe M, Cerrato E, Raposeiras S, Gonzalez A, Franco-Leon F, Wang L, Alfonso E, Ugo F, Garcia-Prieto JF, Feltes G, Abumayyaleh M, Espejo-Paeres C, Jativa J, Masjuan AL, Macaya C, Carbonell Asins JA, Estrada V; HOPE COVID-19 investigators. Prevalence and 30-Day Mortality in Hospitalized Patients With Covid-19 and Prior Lung Diseases. Arch Bronconeumol. 2021 Apr;57:13-20. doi: 10.1016/j.arbres.2020.11.012. Epub 2020 Dec 16.
Reference Type
RESULT
Santoro F, Nunez-Gil IJ, Vitale E, Viana-Llamas MC, Reche-Martinez B, Romero-Pareja R, Feltez Guzman G, Fernandez Rozas I, Uribarri A, Becerra-Munoz VM, Alfonso-Rodriguez E, Garcia-Aguado M, Huang J, Ortega-Armas ME, Garcia Prieto JF, Corral Rubio EM, Ugo F, Bianco M, Mulet A, Raposeiras-Roubin S, Jativa Mendez JL, Espejo Paeres C, Albarran AR, Marin F, Guerra F, Akin I, Cortese B, Ramakrishna H, Macaya C, Fernandez-Ortiz A, Brunetti ND. Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry. Heart. 2022 Jan;108(2):130-136. doi: 10.1136/heartjnl-2021-319552. Epub 2021 Oct 5.
Reference Type
RESULT
Nunez-Gil IJ, Olier I, Feltes G, Viana-Llamas MC, Maroun-Eid C, Romero R, Fernandez-Rozas I, Uribarri A, Becerra-Munoz VM, Alfonso-Rodriguez E, Garcia-Aguado M, Elola J, Castro-Mejia A, Pepe M, Garcia-Prieto JF, Gonzalez A, Ugo F, Cerrato E, Bondia E, Raposeiras-Roubin S, Mendez JLJ, Espejo C, Lopez-Masjuan A, Marin F, Lopez-Pais J, Abumayyaleh M, Corbi-Pascual M, Liebetrau C, Ramakrishna H, Estrada V, Macaya C, Fernandez-Ortiz A; HOPE COVID-19 Investigators (Cols Appendix). Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry. Am Heart J. 2021 Jul;237:104-115. doi: 10.1016/j.ahj.2021.04.001. Epub 2021 Apr 15.
Reference Type
RESULT
Porta-Etessam J, Nunez-Gil IJ, Gonzalez Garcia N, Fernandez-Perez C, Viana-Llamas MC, Eid CM, Romero R, Molina M, Uribarri A, Becerra-Munoz VM, Aguado MG, Huang J, Rondano E, Cerrato E, Alfonso E, Mejia AFC, Marin F, Roubin SR, Pepe M, Feltes G, Mate P, Cortese B, Buzon L, Mendez JJ, Estrada V. COVID-19 anosmia and gustatory symptoms as a prognosis factor: a subanalysis of the HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry. Infection. 2021 Aug;49(4):677-684. doi: 10.1007/s15010-021-01587-9. Epub 2021 Mar 1.
Reference Type
RESULT
Espejo-Paeres C, Nunez-Gil IJ, Estrada V, Fernandez-Perez C, Uribe-Heredia G, Cabre-Verdiell C, Uribarri A, Romero R, Garcia-Aguado M, Fernandez-Rozas I, Becerra-Munoz V, Pepe M, Cerrato E, Raposeiras-Roubin S, Barrionuevo-Ramos M, Aveiga-Ligua F, Aguilar-Andrea C, Alfonso-Rodriguez E, Ugo F, Garcia-Prieto JF, Feltes G, Akin I, Huang J, Jativa J, Fernandez-Ortiz A, Macaya C, Carrero-Fernandez A, Signes-Costa J. Impact of smoking on COVID-19 outcomes: a HOPE Registry subanalysis. BMJ Nutr Prev Health. 2021 Jun 17;4(1):285-292. doi: 10.1136/bmjnph-2021-000269. eCollection 2021.
Reference Type
RESULT
Viana-Llamas MC, Arroyo-Espliguero R, Silva-Obregon JA, Uribe-Heredia G, Nunez-Gil I, Garcia-Magallon B, Toran-Martinez CG, Castillo-Sandoval A, Diaz-Caraballo E, Rodriguez-Guinea I, Dominguez-Lopez J. Hypoalbuminemia on admission in COVID-19 infection: An early predictor of mortality and adverse events. A retrospective observational study. Med Clin (Barc). 2021 May 7;156(9):428-436. doi: 10.1016/j.medcli.2020.12.018. Epub 2021 Jan 28.
Reference Type
RESULT
Abumayyaleh M, Nunez Gil IJ, El-Battrawy I, Estrada V, Becerra-Munoz VM, Aparisi A, Fernandez-Rozas I, Feltes G, Arroyo-Espliguero R, Trabattoni D, Lopez-Pais J, Pepe M, Romero R, Garcia DRV, Biole C, Astrua TC, Eid CM, Alfonso E, Fernandez-Presa L, Espejo C, Buonsenso D, Raposeiras S, Fernandez C, Macaya C, Akin I; HOPE COVID-19 investigators. Does there exist an obesity paradox in COVID-19? Insights of the international HOPE-COVID-19-registry. Obes Res Clin Pract. 2021 May-Jun;15(3):275-280. doi: 10.1016/j.orcp.2021.02.008. Epub 2021 Mar 3.
Reference Type
RESULT
Abumayyaleh M, Nunez-Gil IJ, El-Battrawy I, Estrada V, Becerra-Munoz VM, Uribarri A, Fernandez-Rozas I, Feltes G, Arroyo-Espliguero R, Trabattoni D, Lopez Pais J, Pepe M, Romero R, Ortega-Armas ME, Bianco M, Astrua TC, D'Ascenzo F, Fabregat-Andres O, Ballester A, Marin F, Buonsenso D, Sanchez-Gimenez R, Weiss C, Fernandez Perez C, Fernandez-Ortiz A, Macaya C, Akin I. Sepsis of Patients Infected by SARS-CoV-2: Real-World Experience From the International HOPE-COVID-19-Registry and Validation of HOPE Sepsis Score. Front Med (Lausanne). 2021 Oct 14;8:728102. doi: 10.3389/fmed.2021.728102. eCollection 2021.
Reference Type
RESULT
Perez-Segura P, Paz-Cabezas M, Nunez-Gil IJ, Arroyo-Espliguero R, Maroun Eid C, Romero R, Fernandez Rozas I, Uribarri A, Becerra-Munoz VM, Garcia Aguado M, Huang J, Rondano E, Cerrato E, Rodriguez EA, Ortega-Armas ME, Raposeiras Roubin S, Pepe M, Feltes G, Gonzalez A, Cortese B, Buzon L, El-Battrawy I, Estrada V. Prognostic factors at admission on patients with cancer and COVID-19: Analysis of HOPE registry data. Med Clin (Barc). 2021 Oct 8;157(7):318-324. doi: 10.1016/j.medcli.2021.02.021. Epub 2021 May 6.
Reference Type
RESULT
Salgado-Aranda R, Perez-Castellano N, Nunez-Gil I, Orozco AJ, Torres-Esquivel N, Flores-Soler J, Chamaisse-Akari A, Mclnerney A, Vergara-Uzcategui C, Wang L, Gonzalez-Ferrer JJ, Filgueiras-Rama D, Canadas-Godoy V, Macaya-Miguel C, Perez-Villacastin J. Influence of Baseline Physical Activity as a Modifying Factor on COVID-19 Mortality: A Single-Center, Retrospective Study. Infect Dis Ther. 2021 Jun;10(2):801-814. doi: 10.1007/s40121-021-00418-6. Epub 2021 Mar 14.
Reference Type
RESULT
Bertaina M, Nunez-Gil IJ, Franchin L, Fernandez Rozas I, Arroyo-Espliguero R, Viana-Llamas MC, Romero R, Maroun Eid C, Uribarri A, Becerra-Munoz VM, Huang J, Alfonso E, Marmol-Mosquera F, Ugo F, Cerrato E, Fernandez-Presa L, Raposeiras Roubin S, Feltes Guzman G, Gonzalez A, Abumayyaleh M, Fernandez-Ortiz A, Macaya C, Estrada V; HOPE COVID-19 investigators. Non-invasive ventilation for SARS-CoV-2 acute respiratory failure: a subanalysis from the HOPE COVID-19 registry. Emerg Med J. 2021 May;38(5):359-365. doi: 10.1136/emermed-2020-210411. Epub 2021 Mar 16.
Reference Type
RESULT
Rivera-Caravaca JM, Nunez-Gil IJ, Lip GYH, Uribarri A, Viana-Llamas MC, Gonzalez A, Castro-Mejia AF, Alonso Gonzalez B, Alfonso E, Garcia Prieto JF, Cavallino C, Cortese B, Feltes G, Fernandez-Rozas I, Signes-Costa J, Huang J, Garcia Aguado M, Pepe M, Romero R, Cerrato E, Becerra-Munoz VM, Raposeiras Roubin S, Santoro F, Bagur R, Sposato L, El-Battrawy I, Lopez Masjuan A, Fernandez-Ortiz A, Estrada V, Macaya C, Marin F. Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry. Int J Clin Pract. 2022 May 26;2022:7325060. doi: 10.1155/2022/7325060. eCollection 2022.
Reference Type
DERIVED
El-Battrawy I, Longo F, Nunez Gil IJ, Abumayyaleh M, Gianesin B, Estrada V, Aparisi A, Arroyo-Espliguero R, Balocco M, Barella S, Beccaria A, Bonetti F, Casale M, De Michele E, Denotti AR, Fidone C, Fortini M, Gamberini MR, Graziadei G, Lisi R, Massa A, Marcon A, Rubinski B, Miano M, Motta I, Pinto VM, Piperno A, Mariani R, Putti MC, Quota A, Ribersani M, Marziali M, Roberti D, Rosso R, Tartaglione I, Vitucci A, Voi V, Zecca M, Romero R, Marouneld C, Fernandez-Rozas I, Espejo C, Marhaeni W, Garcia Aguado M, Cappellini MD, Perrotta S, De Franceschi L, Piga A, Forni GL, Akin I. Thalassaemia is paradoxically associated with a reduced risk of in-hospital complications and mortality in COVID-19: Data from an international registry. J Cell Mol Med. 2022 May;26(9):2520-2528. doi: 10.1111/jcmm.17026. Epub 2022 Mar 30.
Reference Type
DERIVED
Biole C, Bianco M, Nunez-Gil IJ, Cerrato E, Spirito A, Roubin SR, Viana-Llamas MC, Gonzalez A, Castro-Mejia AF, Eid CM, Fernandez-Perez C, Uribarri A, Alfonso-Rodriguez E, Ugo F, Guerra F, Feltes G, Akin I, Fernandez-Rozas I, Blasco-Angulo N, Huang J, Aguado MG, Pepe M, Romero R, Becerra-Munoz VM, Estrada V, Macaya C. Gender Differences in the Presentation and Outcomes of Hospitalized Patients With COVID-19. J Hosp Med. 2021 Jun;16(6):349-352. doi: 10.12788/jhm.3594.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EUPAS34399
Identifier Type: OTHER
Identifier Source: secondary_id
20/241-E
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Clinical and Biological Predictors of COVID-19 Disease in Older Patients
NCT04348396
UNKNOWN
Prospective Evaluation of the Predictive Criteria of Severity for Respiratory Infection Due to COVID-19 Virus
NCT04615676
COMPLETED
Outcomes in Hospitalized Older Patients With COVID-19
NCT04385212
COMPLETED
International SARS-CoV-2 (COVID-19) Infection Observational Study
NCT04385251
COMPLETED
Health Professional Exposure Assessment to Covid-19
NCT04429724
COMPLETED
NA
Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients
NCT04324047
UNKNOWN
Risk Factors Worsening COVID19 for Out-patient With Home Monitoring
NCT04380662
UNKNOWN
Post-Covid Condition Cohort: Evolution of Symptomatology, Patient Profile and Associated Prognostic Factors
NCT05610436
RECRUITING
A COVID-19 Symptom, Exposure and Immune Response Registry
NCT04348942
COMPLETED
Active Monitoring And Determinants of Incidence Infection of COVDI-19
NCT04326400
UNKNOWN
COVID-19 Hyperinflammation Syndrome (COV-HI): Protocol for a Rapidly Executed Cohort Study
NCT04385069
UNKNOWN
Risk Factors and Prognoses in Patients Hospitalized for COVID-19
NCT04824677
COMPLETED
Independent Predictors on Clinical Outcomes in SARS-CoV2 Patients
NCT05162534
COMPLETED
Caracterisation of COVID-19 Patients Hospitalized in Infectious Disease Department
NCT04779021
UNKNOWN
Risk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19
NCT04456075
UNKNOWN
Mechanisms for Covid-19 Disease Complications
NCT04314232
UNKNOWN
COVID-19 Survival - The COVIVA Study
NCT04366765
COMPLETED
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study
NCT04365764
COMPLETED
Institutional Registry on Outpatient and Hospitalized COVID-19 Infected Patients
NCT04839107
UNKNOWN
Study of Symptoms Linked to Covid-19 in Residents and Professionals in EHPAD, Associated With a Dual Diagnostic Approach by PCR and Serology: a Cohort in Île-de-France.
NCT04677283
COMPLETED
COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study
NCT04392401
RECRUITING
STUDY OF THE COVID-19 EPIDEMIC AND SOCIO-ECONOMIC LIVING CONDITIONS IN FRANCE
NCT05336604
COMPLETED
Longitudinal Population-based Observational Study of COVID-19 in the UK Population
NCT04330599
RECRUITING
Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19
NCT04581135
COMPLETED
Comorbidities and Risk Score in COVID-19 Patients
NCT04670094
COMPLETED